Recent confusion and ongoing actions related to the FDA’s Inactive Ingredient Database (IID) - What should be included in the ANDA?
The FDA's inactive ingredient database (IID) does not currently provide information on the maximum allowable amount of excipient per day or per dosage form. This had led to significant confusion among generic drug manufacturers, with excipient amounts chosen not from the standpoint of the most...
Main Author: | David R. Schoneker |
---|---|
Format: | Article |
Language: | English |
Published: |
International Pharmaceutical Excipients Council
2016-10-01
|
Series: | Journal of Excipients and Food Chemicals |
Online Access: | https://jefc.scholasticahq.com/article/924-recent-confusion-and-ongoing-actions-related-to-the-fda-s-inactive-ingredient-database-iid-what-should-be-included-in-the-anda |
Similar Items
-
The effects of lobbying on the FDA’s recall classification
by: Yifan Zhou
Published: (2023-06-01) -
Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
by: Sarah Lee, et al.
Published: (2023-11-01) -
A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
by: Sarfaraz K. Niazi
Published: (2023-11-01) -
Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
by: Joseph S Ross, et al.
Published: (2023-10-01) -
The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
by: Sarfaraz K. Niazi
Published: (2023-10-01)